Table 3.
Summary of the Incidence of Drug Interruption in Patients Treated with Cabozantinib, Nivolumab, or with First-Line Combination Therapies
| Agents (Trial) | Setting | Incidence of Interruption (%) | Reference |
|---|---|---|---|
| Cabozantinib (METEOR) | L2+ | 9 | Choueiri NEJM 201513 |
| Ipilimumab+Nivolumab (Checkmate 214) ITT | L1 | 22.1 | Motzer NEJM 202132 |
| Axitinib+Pembrolizumab (Keynote 426) | L1 | 25.9 -21%pembrolizumab only |
Rini NEJM 201934 |
| -20% axitinib only | |||
| -7% both | |||
| Cabozantinib + nivolumab (Checkmate 9ER) | L1 | 19.7 -6.6% nivolumab only -7.5% cabozantinib onlyseul -5.6% both |
Choueiri NEJM 202135 |
| Lenvatinib + Pembrolizumab (CLEAR) | L1 | 37.2 –28.7% pembrolizumab -25.6% lenvatinib onlyseul -13.4% both |
Motzer NEJM 202137 |
Note: L, treatment line.